

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Susan P. Whitman, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, and Clara D. Bloomfield

See accompanying article on page 2356

A B S T R A C T

Purpose

To analyze the frequency and associations with prognostic markers and outcome of mutations in *IDH* genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML).

Patients and Methods

Diagnostic bone marrow or blood samples from 358 patients were analyzed for *IDH1* and *IDH2* mutations by DNA polymerase chain reaction amplification/sequencing. *FLT3*, *NPM1*, *CEBPA*, *WT1*, and *MLL* mutational analyses and gene- and microRNA-expression profiling were performed centrally.

Results

IDH mutations were found in 33% of the patients. *IDH1* mutations were detected in 49 patients (14%; 47 with R132). *IDH2* mutations, previously unreported in AML, were detected in 69 patients (19%; 13 with R172 and 56 with R140). R172 *IDH2* mutations were mutually exclusive with all other prognostic mutations analyzed. Younger age (< 60 years), molecular low-risk (*NPM1*-mutated/*FLT3*-internal tandem duplication-negative) *IDH1*-mutated patients had shorter disease-free survival than molecular low-risk *IDH1*/*IDH2*-wild-type (wt) patients ($P = .046$). R172 *IDH2*-mutated patients had lower complete remission rates than *IDH1*/*IDH2*wt patients ($P = .007$). Distinctive microarray gene- and microRNA-expression profiles accurately predicted R172 *IDH2* mutations. The highest expressed gene and microRNAs in R172 *IDH2*-mutated patients compared with the *IDH1*/*IDH2*wt patients were *APP* (previously associated with complex karyotype AML) and *miR-1* and *miR-133* (involved in embryonal stem-cell differentiation), respectively.

Conclusion

IDH1 and *IDH2* mutations are recurrent in CN-AML and have an unfavorable impact on outcome. The R172 *IDH2* mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms.

J Clin Oncol 28:2348-2355. © 2010 by American Society of Clinical Oncology

INTRODUCTION

Despite progress in understanding mechanisms of leukemogenesis and improvement in treatment, only approximately 40% of younger (age < 60 years) and 10% of older (age ≥ 60 years) adults with acute myeloid leukemia (AML) achieve long-term survival.¹⁻⁴ These results underscore the need for novel therapeutic strategies that would improve outcome. To this end, identification of subsets of

patients with distinct clinical and biologic features that would help to stratify them to specific risk-adapted and/or molecularly targeted therapies is imperative.^{5,6}

Cytogenetically normal AML (CN-AML) is the largest group among both younger and older AML patients and the best characterized molecularly.⁵⁻⁷ During the last 15 years, recurring mutations with prognostic significance in genes such as *FLT3*,^{8,9} *NPM1*,^{10,11} *CEBPA*,^{12,13} *WT1*,^{14,15} and *MLL*^{16,17}

From the Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH; The Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC; University of Iowa, Iowa City, IA; North Shore University Hospital, Manhasset; Roswell Park Cancer Institute, Buffalo, NY; University of Alabama at Birmingham, Birmingham, AL; University of Maryland, Baltimore, MD; and University of Chicago, Chicago, IL.

Submitted November 28, 2009; accepted January 27, 2010; published online ahead of print at www.jco.org on April 5, 2010.

Supported in part by National Cancer Institute Grants No. CA101140, CA114725, CA31946, CA33601, CA16058, CA77658, CA129657, and CA140158, by The Coleman Leukemia Research Foundation, and by the Deutsche Krebshilfe Dr Mildred Scheel Cancer Foundation (H.B.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Clara D. Bloomfield, MD, Comprehensive Cancer Center, The Ohio State University, 1216 James Cancer Hospital, 300 W. 10th Ave, Columbus, OH 43210; e-mail: clara.bloomfield@osumc.edu.

© 2010 by American Society of Clinical Oncology

0732-183X/10/2814-2348/\$20.00

DOI: 10.1200/JCO.2009.27.3730

have been identified in de novo CN-AML. These markers are not mutually exclusive, and combinations of them may further refine prediction of the risk of adverse events. Thus, patients who carry an *NPM1* mutation but not an *FLT3* internal tandem duplication (ITD) are in the molecular low-risk group because they have a better outcome than patients who lack *NPM1* mutations and/or carry an *FLT3*-ITD and therefore are in the molecular high-risk group.^{5,6} Among the latter, however, those who also harbor *CEBPA* mutations have outcomes similar to that of patients with mutated *NPM1* and no *FLT3*-ITD.¹³ While the majority of CN-AML patients harbor one or more of the aforementioned mutations, in approximately 15% of the patients, no mutations have been detected,¹⁸ suggesting the existence of hitherto undiscovered genetic alterations contributing to leukemogenesis and defining molecular risk for these patients.

Recent studies revealed that mutations in *IDH1* and *IDH2*, the genes encoding isoforms of the nicotinamide adenine dinucleotide phosphate-dependent isocitrate dehydrogenases, are recurrent in brain tumors, including WHO grade 4 gliomas and WHO grade 2 and 3 astrocytomas and oligodendrogliomas, and are associated with favorable outcome.^{19,20} Importantly, an *IDH1* mutation was also discovered through massively parallel DNA sequencing analysis of the genome of a patient with CN-AML.²¹ In the same study,²¹ 15 *IDH1* mutations, but no *IDH2* mutations, were also found in a validation set of 187 AML patients. An analysis of overall survival (OS) of this patient population (n = 188), which was heterogeneous with regard to AML type (de novo *v* secondary), age, and cytogenetics, showed no independent prognostic significance of *IDH1* mutations. However, a subgroup analysis showed that *IDH1* mutations were associated with CN-AML, being detected in 13 (16%) of 80 such patients, and that they conferred adverse prognosis in the absence of *NPM1* mutations.²¹

To corroborate these preliminary data, we analyzed *IDH1* and *IDH2* mutations in a homogeneous cohort of 358 adults with de novo CN-AML treated with age-adapted intensive chemotherapy regimens on Cancer and Leukemia Group B (CALGB) first-line protocols and comprehensively characterized other gene mutations associated with outcome.

PATIENTS AND METHODS

Patients, Cytogenetic Analysis, and Treatment

We studied pretreatment bone marrow and blood samples with $\geq 20\%$ blasts from 358 patients age 19 to 83 years with de novo CN-AML. Cytogenetic analyses at diagnosis were confirmed by central karyotype review.²² To establish CN-AML, ≥ 20 metaphase cells from diagnostic bone marrow had to be analyzed and the karyotype had to be normal.²³ Institutional review board–approved informed consent for participation in the studies was obtained from all patients. Younger patients (age < 60 years; n = 159) were treated on CALGB 9621²⁴ and 19808²⁵ protocols and older patients (age ≥ 60 years; n = 199) were enrolled on protocols 8525,²⁶ 8923,²⁷ 9420,²⁸ 9720,²⁹ or 10201³⁰ (for treatment details, see Appendix, online only). No patient included in our analysis received allogeneic transplantation in first complete remission (CR). The median follow-up for younger and older patients alive and included in this analysis was 7.0 and 3.8 years, respectively.

Molecular Analyses

For *IDH1* and *IDH2* mutational analyses, DNA fragments spanning exons 4 of *IDH1* and *IDH2*, previously identified as “hot spots” for mutations in these genes,²⁰ were amplified by polymerase chain reaction and directly sequenced as detailed in the Appendix. Other molecular markers—*FLT3*-

ITD,⁹ *FLT3* tyrosine kinase domain (*FLT3*-TKD) mutations,³¹ *MLL* partial tandem duplication (*MLL*-PTD),^{17,32} and mutations in the *NPM1*,³³ *CEBPA*,¹³ and *WT1*¹⁴ genes—were assessed centrally as previously reported.

Genome-Wide Expression Analyses

Gene- and microRNA-expression profiling were conducted using the Affymetrix U133 Plus 2.0 array (Affymetrix, Santa Clara, CA) and the Ohio State University custom microRNA array (OSU_CCC version 4.0), respectively, as reported previously,^{34,35} and described in the Appendix.

Statistical Analysis

Definitions of clinical end points—CR, disease-free survival (DFS), and OS—are provided in the Appendix. The differences among patients in baseline clinical and molecular features according to their *IDH1* and *IDH2* mutational status were tested using the Fisher's exact and Wilcoxon rank sum tests for categorical and continuous variables, respectively. Estimated probabilities of DFS and OS were calculated using the Kaplan-Meier method, and the log-rank test evaluated differences between survival distributions.

For expression profiling, summary measures of gene- and microRNA-expression levels were computed, normalized, and filtered (see Appendix). Expression signatures were derived by comparing gene- and microRNA-expression levels among patients with distinct types of *IDH* mutations and patients with wild-type *IDH1* and *IDH2* (*IDH1*/*IDH2*wt). Univariable significance levels of 0.001 for gene- and 0.005 for microRNA-expression profiling were used to determine the gene probe sets and microRNA probes comprising the signatures, respectively. Prediction of *IDH* mutation status using gene- and microRNA-expression profiles is described in the Appendix. All analyses were performed by the CALGB Statistical Center.

RESULTS

Frequency of IDH2 and IDH1 Mutations

Of the 358 AML patients analyzed, 118 (33%) harbored missense mutations in *IDH* genes. Forty-nine patients (14%) had *IDH1* mutations, including R132 mutations detected in 46 patients, V71 in two patients, and concurrent R132 and V71 mutations in one patient (Table 1). Sixty-nine patients (19%) had *IDH2* mutations: 56 were R140 and 13 were R172 mutations (Table 1). No patient had both *IDH1* and *IDH2* mutations.

Associations of IDH Mutations With Pretreatment Characteristics

Comparisons of pretreatment clinical characteristics of *IDH1*- or *IDH2*-mutated patients with those of *IDH1*/*IDH2*wt patients are reported in Table 2. All types of *IDH* mutations were significantly associated with higher platelet counts, *IDH2* mutations were associated with older age, and R172 *IDH2* mutations were associated with low WBC and a low percentage of circulating blasts.

At diagnosis, patients with *IDH1* mutations were less frequently *FLT3*-ITD–positive ($P = .02$), were more often categorized in the molecular low-risk group (*NPM1*-mutated/*FLT3*-ITD–negative; $P = .003$), and had a trend for lower frequencies of *WT1* ($P = .06$) and *CEBPA* mutations ($P = .08$) compared with *IDH1*/*IDH2*wt patients (Table 3).

Patients with R140 *IDH2* mutations had a lower frequency of *WT1* mutations ($P = .007$) than *IDH1*/*IDH2*wt patients. Strikingly, patients with R172 *IDH2* mutations did not carry any other prognostic mutations, including *FLT3*-ITD, *FLT3*-TKD, *MLL*-PTD, or mutations in the *NPM1*, *WT1*, or *CEBPA* genes (Table 3).

Table 1. Types of *IDH1* and *IDH2* Mutations in CN-AML

<i>IDH1</i> Mutations			<i>IDH2</i> Mutations		
Nucleotide Change	Amino Acid Change	No. of Patients	Nucleotide Change	Amino Acid Change	No. of Patients
c.395G>A	R132H	23	c.419G>A	R140Q	53
c.394C>T	R132C	15	c.418C>T	R140W	1
c.394C>A	R132S	5			
c.394C>G		3	c.418G>T	R140L	2
c.211G>A	V71I	2	c.515G>A	R172K	13
c.395G>A and c.211G>A	R132H & V71I	1		—	—

NOTE. All mutations are missense mutations. The letters in the Amino Acid Change columns denote which amino acid from the wild-type sequence (first letter) is substituted by another amino acid in the mutated sequence (second letter). The number between the letters denotes the codon position. Amino acid abbreviations: C, cysteine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; Q, glutamine; R, arginine; S, serine; V, valine; W, tryptophan. Abbreviations: CN, cytogenetically normal; AML, acute myeloid leukemia.

Associations of *IDH* Mutations With Clinical Outcome

Considering all patients with *IDH1* mutations, there was no difference in outcome compared with *IDH1/IDH2wt* patients (Appendix Table A1, online only). However, in an age group–stratified analysis, we observed a prognostic impact of *IDH1* mutations on the subset of younger (age < 60 years) patients in the molecular low-risk group (*NPM1*-mutated/*FLT3*-ITD–negative). *IDH1*-mutated patients (all with R132 *IDH1* mutation; see Appendix Table A2, online only for other clinical and molecular characteristics) had a significantly worse DFS ($P = .046$; 5-year DFS rates, 42% v 59%) and a trend for worse OS ($P = .14$; 5-year OS rates, 50% v 63%) compared with *IDH1/IDH2wt* patients (Figs 1A and 1B).

With regard to *IDH2* mutations, the outcome of patients with R140 *IDH2* mutations did not differ significantly from the outcome of *IDH1/IDH2wt* patients (Appendix Table A1). However, R172 *IDH2*-mutated patients had a significantly lower CR rate than those with *IDH1/IDH2wt* (38% v 75%; $P = .007$; Fig 1C). When analysis was limited to older patients, who represented most patients with this mutation (77%), those with R172 *IDH2* mutations had a lower CR rate (20% v 67%; $P = .005$) than *IDH1/IDH2wt* patients (Fig 1C). The estimated 3-year OS rates were 0% versus 17% for older patients with R172 *IDH2* mutations compared with *IDH1/IDH2wt* patients, but the difference in OS duration for the two groups was not significant.

Table 2. Clinical Characteristics According to *IDH* Mutational Status in De Novo Cytogenetically Normal Acute Myeloid Leukemia

Clinical Characteristic	<i>IDH1</i> -Mutated (n = 49)		R140 <i>IDH2</i> -Mutated (n = 56)		R172 <i>IDH2</i> -Mutated (n = 13)		<i>IDH1/IDH2wt</i> (n = 240)		<i>P</i> (<i>IDH1</i> -Mutated v <i>IDH1/IDH2wt</i>)	<i>P</i> (R140 <i>IDH2</i> -Mutated v <i>IDH1/IDH2wt</i>)	<i>P</i> (R172 <i>IDH2</i> -Mutated v <i>IDH1/IDH2wt</i>)
	No.	%	No.	%	No.	%	No.	%			
Age, years									.49	.006	.02
Median	62		64		70		60				
Range	21-82		29-83		38-83		19-81				
Male sex	23	47	32	57	7	54	118	49	.88	.30	.78
Race									.10	.78	.30
White	41	84	52	95	11	85	218	92			
Nonwhite	8	16	3	5	2	15	19	8			
Hemoglobin, g/dL									.73	.08	.77
Median	9.3		9.8		9.4		9.3				
Range	7.1-12.9		4.8-13.6		7.7-12.3		4.6-15.0				
Platelet count, ×10 ⁹ /L									<.001	.008	<.001
Median	98		73		131		53				
Range	11-850		11-270		64-309		7-510				
WBC count, ×10 ⁹ /L									.18	.30	<.001
Median	24.6		22.5		1.5		28.4				
Range	0.9-152.1		1.1-434.1		0.9-10.5		0.9-450.0				
Percentage of PB blasts									.26	.85	.002
Median	59		45		7		50				
Range	0-99		0-97		0-79		0-97				
Percentage of BM blasts									.06	.27	.58
Median	73		74		66		63				
Range	33-99		25-96		30-86		7-99				
Extramedullary involvement	11	24	12	22	1	8	75	32	.38	.19	.12

Abbreviations: wt, wild-type; PB, peripheral blood; BM, bone marrow.

Table 3. Molecular Characteristics According to IDH Mutational Status in De Novo Cytogenetically Normal Acute Myeloid Leukemia

Molecular Characteristic	IDH1-Mutated (n = 49)		R140 IDH2-Mutated (n = 56)		R172 IDH2-Mutated (n = 13)		IDH1/IDH2wt (n = 240)		P (IDH1-Mutated v IDH1/IDH2wt)	P (R140 IDH2-Mutated v IDH1/IDH2wt)	P (R172 IDH2-Mutated v IDH1/IDH2wt)
	No.	%	No.	%	No.	%	No.	%			
<i>NPM1</i>									.19	.76	< .001
Mutated	34	71	31	57	0	0	143	60			
Wild-type	14	29	23	43	13	100	96	40			
<i>FLT3-ITD</i>									.02	.12	.005
Present	10	20	15	27	0	0	91	38			
Absent	39	80	41	73	13	100	149	62			
Molecular risk group*									.003	.63	.01
Low	27	55	19	35	0	0	75	31			
High	22	45	35	65	13	100	164	69			
<i>FLT3-TKD</i>									.32	.47	.37
Present	3	6	4	7	0	0	29	12			
Absent	45	94	50	93	13	100	210	88			
<i>WT1</i>									.06	.007	.37
Mutated	1	2	0	0	0	0	27	11			
Wild-type	47	98	54	100	13	100	211	89			
<i>CEBPA</i>									.08	.13	.13
Mutated	2	6	4	9	0	0	38	18			
Wild-type	34	94	42	91	13	100	169	82			
<i>MLL-PTD</i>									.32	1.00	1.00
Present	1	2	3	6	0	0	16	7			
Absent	44	98	49	94	12	100	215	93			

Abbreviations: wt, wild-type; ITD, internal tandem duplication; TKD, tyrosine kinase domain; PTD, partial tandem duplication.
*Molecular low risk: *NPM1* mutated and *FLT3-ITD*-negative; high risk: *NPM1* wild-type and/or *FLT3-ITD*-positive.

Since R172 IDH2 mutations were mutually exclusive with *NPM1* mutations, to account for the potentially favorable clinical impact of *NPM1* mutations on achievement of CR,³³ we compared the outcome of patients with R172 IDH2 mutations with that of IDH1/IDH2wt patients without *NPM1* mutations. We focused only on older patients because they represented the vast majority of patients with R172 IDH2 mutation. In this prognostically unfavorable subset, patients with R172 IDH2 mutations showed a trend for a lower CR rate (20% v 56%; *P* = .08).

Biologic Insights Concerning R172 IDH2 Mutations

To gain biologic insights into the potentially unfavorable prognostic significance of R172 IDH2 mutations, which are mutually exclusive with any other prognostically relevant mutations and therefore likely to identify a novel subset of CN-AML, we derived a gene-expression signature by comparing R172 IDH2-mutated patients with IDH1/IDH2wt patients. Because 77% of patients with R172 IDH2 mutations were older, to eliminate age-dependent bias, we analyzed only patients age ≥ 60 years. Of the 451 differentially expressed probe sets (*P* < .001), 365 were upregulated and 86 were downregulated in patients with R172 IDH2 mutations (Fig 2A; Appendix Table A3, online only).

To assess the accuracy of this gene-expression signature to correctly identify R172 IDH2-mutated patients versus those with IDH1/IDH2wt, we conducted a leave-one-out cross-validated prediction analysis. The mutation status of 95.5% of patients (including five of six R172 IDH2-mutated patients) was correctly predicted (Table 4).

Among the most upregulated probe sets in R172 IDH2-mutated patients were those representing *APP* (nine-fold), *CXCL12* (eight-

fold), *PAWR* (eight-fold), *CDC42BPA* (eight-fold), and *SPARC* (seven-fold; Appendix Table A3). *APP* was previously reported to be upregulated in AML patients with complex karyotype.³⁶ Polymorphism in *CXCL12* (also known as *SDF1*) was associated with increased circulating blasts and extramedullary disease in AML.³⁷ *PAWR* was found to regulate *WT1* activity and to be overexpressed in myelodysplastic syndromes progressing to AML.³⁸ In addition, *CDC42BPA*, although not directly associated with AML, seemingly participates in tumor cell invasion.³⁹ In contrast, *SPARC*, encoding a matricellular glycoprotein with growth-inhibitory and antiangiogenic functions, was found to have lower expression in *MLL*-associated AML and tumor suppressor activity.⁴⁰ Other genes of interest upregulated in the R172 IDH2-mutated patients were *ID1* (four-fold), whose expression was recently correlated with poor outcome in AML⁴¹; *ABCB1* (*MDR1*; five-fold) mediating chemoresistance⁴²; and *KRAS2* (2.6-fold), which is constitutively activated in several human cancers including AML.⁴³

The downregulated genes we found include *KYNU*, which encodes a protein participating in the biosynthesis of NAD cofactors from tryptophan⁴⁴; *SUCLG2*, involved in the Krebs cycle and mutated in Leigh-like syndrome⁴⁵; *CD93*, involved in regulating phagocytosis of apoptotic cells and angiogenesis⁴⁶; *LY86* and *LIST1*, associated with immune response pathways^{47,48}; and *PTHR2*, a receptor for the parathyroid hormone.⁴⁹ To the best of our knowledge, none of these genes have previously been associated with AML.

Genome-wide profiling identifies aberrantly expressed microRNAs associated with distinct molecular subsets of CN-AML patients.⁵⁰ Therefore, we derived a microRNA-expression signature associated with older R172 IDH2-mutated CN-AML. The signature




Fig 1. Impact of distinct *IDH* mutation types on clinical outcome of patients with cytogenetically normal acute myeloid leukemia. (A) Disease-free survival and (B) overall survival of younger molecular low-risk patients according to *IDH1* mutation status. (C) Complete remission rates according to R172 *IDH2* mutation status. ITD, internal tandem duplication; wt, wild-type; CR, complete remission.

comprised 24 differentially expressed ($P < .005$) probes, 13 of which were upregulated and 11 of which were downregulated in R172 *IDH2*-mutated patients (Fig 2B; Appendix Table A4, online only). In leave-one-out cross-validated prediction analysis, the muta-




Fig 2. Genome-wide gene- and microRNA-expression profiles associated with R172 *IDH2* mutations. (A) Gene-expression and (B) microRNA-expression signatures, derived from comparing older patients with R172 *IDH2* mutations and those with the wild-type *IDH1/IDH2* genes. Rows represent gene probe sets (A) or microRNA probes (B), and columns represent patients. Patients are grouped by *IDH2* mutational status (R172 or wild-type). Expression values of the probe sets and microRNA probes are represented by color: green indicates expression less than the median value and red indicates expression greater than the median value for the given gene probe set or microRNA probe.

tion status of 93.2% of patients (including five of six R172 *IDH2*-mutated patients) was correctly predicted (Table 4).

Among the microRNAs most upregulated (> four-fold) in R172 *IDH2*-mutated patients were members of the *miR-125* family (*miR-125a-5p* and *miR-125b*), *miR-1*, and *miR-133*. *miR-125b* has been shown to target the tumor suppressor gene *TP53* and inhibit myeloid differentiation,⁵¹ whereas *miR-1* and *miR-133* have not been previously associated with human cancer, but they participate in cell fate decision mechanisms of pluripotent embryonic stem cells.⁵² Among the most downregulated probes were those representing *mir-194-1*, *miR-526*, *miR-520a-3p*, and *mir-548b*, none of which have previously been associated with normal hematopoiesis or AML.

Table 4. Accuracy of Prediction of the R172 *IDH2* Mutational Status in Older CN-AML Using Leave-One-Out Cross-Validated Prediction Analysis From Gene- and MicroRNA-Expression Profiles

Classification	Overall Accuracy (%)	Sensitivity (%)	Specificity (%)
Gene-expression signature			
R172 (n = 6) v wild-type (n = 83)	95.5	83.3	96.4
MicroRNA-expression signature			
R172 (n = 6) v wild-type (n = 82)	93.2	83.3	93.9

Abbreviations: CN, cytogenetically normal; AML, acute myeloid leukemia.

DISCUSSION

Mutations in the *IDH1* and *IDH2* genes have been found in patients with glioma and predict favorable outcome.¹⁹ Using whole-genome sequencing and validation analyses, Mardis et al²¹ recently reported that *IDH1* mutations can also be found in AML and are associated with normal karyotypes. Therefore, we analyzed a larger, more homogeneous cohort of de novo CN-AML (n = 358), comprising both younger and older patients treated with age-adapted chemotherapy regimens on first-line CALGB clinical trials.

The first salient finding of our study was that we not only confirmed the presence of *IDH1* mutations but also found previously unreported *IDH2* mutations in CN-AML.⁵ *IDH1* mutations were found in 14% of our patients, which is similar to the findings of Mardis et al.²¹ In addition to the previously reported R132 *IDH1* mutations, we identified three patients with a V71I *IDH1* allele. Although this allele has been recently reported as a single nucleotide polymorphism (SNP), Bleeker et al⁵³ did not find it in any of the 672 tumor samples and 84 cell lines they sequenced. This suggests that if V71I *IDH1* is an SNP, it is rare and, therefore, the possibility that V71I *IDH1* represents a novel *IDH1* somatic or germline mutation associated with AML cannot be excluded.

Moreover, unlike Mardis et al,²¹ we also detected two different types of mutations in the *IDH2* gene (ie, R140 and R172), which occurred with even greater frequency (19%) and, to the best of our knowledge, have not been previously reported in AML. Interestingly, while the R172 *IDH2* mutation was previously found in gliomas, to the best of our knowledge, the R140 *IDH2* mutation has not been previously reported in human cancer or normal tissue. Since changes in codon 140 detected in our patients led to the substitution of the arginine with three different amino acids (Table 1), it is likely that R140 *IDH2* represents a somatic mutation associated with AML rather than a newly discovered SNP. Studies of normal tissues from R140 *IDH2* AML patients are underway to confirm (or refute) the somatic nature of R140 *IDH2*. Both *IDH2* mutations were associated with older age but, remarkably, only R172 *IDH2* mutations were found in the absence of other recurrent mutations thereby identifying a novel subset of patients among those 15% of CN-AML patients for whom no prognostic gene mutation has been hitherto reported. When considered together, the frequency of mutations in genes encoding the isocitrate dehydrogenases is relatively high in CN-AML (33%), placing them among the most frequent mutations in CN-AML.

The second important finding relates to the prognostic significance of *IDH* mutations in specific age and molecular subsets of CN-AML. We showed that although *IDH1* mutations did not affect outcome in the whole cohort of CN-AML patients, they conferred worse prognosis in younger patients with molecular low-risk CN-AML. These results differ from two previous studies reporting that *IDH1* mutations conferred adverse outcome in *NPM1*wt patients with CN-AML²¹ or various karyotypes.⁵⁴ Differences in sizes of patient cohorts analyzed, varying inclusion criteria (eg, we studied only de novo AML patients whereas Schnittger et al⁵⁴ also analyzed secondary AML), age, and treatment administered might contribute to these discrepancies among studies, which require further investigation for resolution.

Most patients with R172 *IDH2* mutations failed to achieve a CR following intensive cytarabine/anthracycline-based induction chemotherapy. Because *NPM1* mutations are a strong, favorable prognosticator in older CN-AML patients,³³ we also separately analyzed older patients without *NPM1* mutations; even then, the CR rate of patients with R172 *IDH2* mutations tended to be lower than that of *IDH1*/*IDH2*wt patients. These results suggest that it is the presence of the R172 *IDH2* mutation itself rather than the absence of *NPM1* mutations that decreases the odds of achieving CR. However, given the relatively small number of R172 *IDH2*-mutated patients in our cohort, larger studies should corroborate our results. Notably, in contrast with our data in CN-AML, R172 *IDH2* mutations were reported to predict a favorable outcome in patients with gliomas,²⁰ thereby supporting the notion that the prognostic significance of molecular markers may vary according to distinct biologic and/or therapeutic contexts in which they are evaluated. Furthermore, in contrast with R172 *IDH2* mutations, the outcome of patients with R140 *IDH2* mutations was not different from the outcome of patients with wt *IDH1* and *IDH2* genes, thereby suggesting different contributions to leukemogenesis from these two mutation types.

Finally, we showed that R172 *IDH2* mutations in CN-AML are associated with unique gene- and microRNA-expression signatures. Although the signature did not include previously reported unfavorable prognosticators in CN-AML (ie, *BAALC*, *ERG*, and *MN1*),⁵⁵⁻⁶¹ it comprised other upregulated genes associated with adverse karyotypes (*APP*),³⁶ unfavorable outcome (*IDI1*),⁴¹ increased rate of extramedullary disease (*CXCL12*),³⁷ or increased chemoresistance (*ABCB1*) in AML,⁴² supporting the negative prognostic significance of this mutation type. Furthermore, among microRNAs differentially expressed in R172 *IDH2*-mutated patients, we noted upregulation of *miR-125b*, previously found to block myeloid differentiation,⁵¹ and *miR-1* and *miR-133*, not reported previously in AML but involved in embryonal stem-cell differentiation.⁵² Importantly, both gene- and microRNA-expression signatures appeared to predict the R172 *IDH2* mutational status with high accuracy, thus supporting the view that patients with R172 *IDH2* mutations profoundly differ biologically and clinically from patients with wt *IDH1* and *IDH2* alleles.

The mechanisms through which *IDH1* and *IDH2* mutations contribute to malignant transformation are under investigation. Thompson⁶² postulated that *IDH1* and *IDH2* mutations result in gain rather than loss of function, given the high frequency of somatic mutations affecting a single codon and the absence of other mutations causing gene inactivation. Indeed, Dang et al⁶³ showed that the R132 *IDH1* mutation causes the encoded enzyme to acquire the ability to convert α -ketoglutarate to 2-hydroxy-glutarate, which accumulates in

the affected cells. This likely contributes to malignant transformation since inborn errors of 2-hydroxy-glutarate metabolism have been associated with an increased risk of brain tumors.⁶³ While similar mechanisms might be operative in patients harboring *IDH2* mutations, to the best of our knowledge, no functional study of the mutant proteins has been reported.

In summary, we report here that *IDH1* mutations predict shorter DFS in younger molecular low-risk CN-AML patients, R172 *IDH2* mutations are mutually exclusive with other known prognostic mutations and denote a novel subset of older CN-AML patients characterized by resistance to induction chemotherapy, and R140 *IDH2* mutations do not appear to confer prognostic significance. By deriving gene- and microRNA-expression signatures, we uncovered intriguing features in R172 *IDH2*-mutated patients that may lead to better understanding of the biologic role of this mutation and to the design of novel therapies targeting aberrant isocitrate dehydrogenase-driven activation of metabolic pathways.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCES

1. Estey E, Döhner H: Acute myeloid leukaemia. *Lancet* 368:1894-1907, 2006
2. Farag SS, Ruppert AS, Mrózek K, et al: Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. *J Clin Oncol* 23:482-493, 2005
3. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. *Blood* 107:3481-3485, 2006
4. Estey E: Acute myeloid leukemia and myelodysplastic syndromes in older patients. *J Clin Oncol* 25:1908-1915, 2007
5. Mrózek K, Marcucci G, Paschka P, et al: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? *Blood* 109:431-448, 2007
6. Gaidzik V, Döhner K: Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. *Semin Oncol* 35:346-355, 2008
7. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. *Blood Rev* 18:115-136, 2004
8. Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult *de novo* acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of *FLT3*: A Cancer and Leukemia Group B study. *Cancer Res* 61:7233-7239, 2001
9. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. *Blood* 99:4326-4335, 2002
10. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia

with a normal karyotype. *N Engl J Med* 352:254-266, 2005

11. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (*NPM1*) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. *Blood* 106:3740-3746, 2005
12. Fröhling S, Schlenk RF, Stolze I, et al: *CEBPA* mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. *J Clin Oncol* 22:624-633, 2004
13. Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, *CEBPA* mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. *J Clin Oncol* 26:5078-5087, 2008
14. Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. *J Clin Oncol* 26:4595-4602, 2008
15. Virappane P, Gale R, Hills R, et al: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. *J Clin Oncol* 26:5429-5435, 2008
16. Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangement of *ALL1* (*MLL*) in acute myeloid leukemia with normal cytogenetics. *Cancer Res* 58:55-59, 1998
17. Whitman SP, Ruppert AS, Marcucci G, et al: Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and *MLL* partial tandem duplication: A Cancer and Leukemia Group B study. *Blood* 109:5164-5167, 2007
18. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international

AUTHOR CONTRIBUTIONS

Conception and design: Guido Marcucci, Clara D. Bloomfield
Financial support: Guido Marcucci, Clara D. Bloomfield
Administrative support: Michael A. Caligiuri, Clara D. Bloomfield
Provision of study materials or patients: Guido Marcucci, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield
Collection and assembly of data: Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D. Radmacher, Susan P. Whitman, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Andrew J. Carroll, Clara D. Bloomfield
Data analysis and interpretation: Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Clara D. Bloomfield
Manuscript writing: Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Susan P. Whitman, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Clara D. Bloomfield
Final approval of manuscript: Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Susan P. Whitman, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield

expert panel, on behalf of the European Leukemia-Net. *Blood* 115:453-474, 2010

19. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. *Science* 321:1807-1812, 2008
20. Yan H, Parsons DW, Jin G, et al: *IDH1* and *IDH2* mutations in gliomas. *N Engl J Med* 360:765-773, 2009
21. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 361:1058-1066, 2009
22. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with *de novo* acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). *Blood* 100:4325-4336, 2002
23. Mrózek K, Carroll AJ, Maharry K, et al: Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience. *Int J Oncol* 33:239-244, 2008
24. Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B study 9621. *J Clin Oncol* 22:4290-4301, 2004
25. Kolitz JE, George SL, Marcucci G, et al: A randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients < 60 years using P-glycoprotein (Pgp) modulation with Valspodar (PSC833): Preliminary results of Cancer and Leukemia Group B study 19808. *Blood* 106:122a-123a, 2005 (abstr 407)
26. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. *N Engl J Med* 331:896-903, 1994

27. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. *N Engl J Med* 332:1671-1677, 1995
28. Lee EJ, George SL, Caligiuri M, et al: Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420. *J Clin Oncol* 17:2831-2839, 1999
29. Baer MR, George SL, Caligiuri MA, et al: Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. *J Clin Oncol* 26:4934-4939, 2008
30. Marcucci G, Moser B, Blum W, et al: A phase III randomized trial of intensive induction and consolidation chemotherapy \pm oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients > 60 years old. *J Clin Oncol* 25:360s, 2007 (suppl; abstr 7012)
31. Whitman SP, Ruppert AS, Radmacher MD, et al: *FLT3* D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking *FLT3* internal tandem duplications. *Blood* 111:1552-1559, 2008
32. Caligiuri MA, Strout MP, Schichman SA, et al: Partial tandem duplication of *ALL1* as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. *Cancer Res* 56:1418-1425, 1996
33. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of *NPM1* mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. *J Clin Oncol* 28:596-604, 2010
34. Radmacher MD, Marcucci G, Ruppert AS, et al: Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: A Cancer and Leukemia Group B study. *Blood* 108:1677-1683, 2006
35. Calin GA, Liu CG, Sevignani C, et al: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proc Natl Acad Sci U S A* 101:11755-11760, 2004
36. Baldus CD, Liyanarachchi S, Mrózek K, et al: Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of *APP*, *ETS2*, and *ERG* genes. *Proc Natl Acad Sci U S A* 101:3915-3920, 2004
37. Zeng Z, Shi YX, Samudio IJ, et al: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. *Blood* 113:6215-6224, 2009
38. Mahadevan D, DiMento J, Croce KD, et al: Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia. *Am J Hematol* 81:779-786, 2006
39. Wilkinson S, Paterson HF, Marshall CJ: Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. *Nat Cell Biol* 7:255-261, 2005
40. DiMartino JF, Lacayo NJ, Varadi M, et al: Low or absent *SPARC* expression in acute myeloid leukemia with *MLL* rearrangements is associated with sensitivity to growth inhibition by exogenous *SPARC* protein. *Leukemia* 20:426-432, 2006
41. Tang R, Hirsch P, Fava F, et al: High *Id1* expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. *Blood* 114:2993-3000, 2009
42. Mahadevan D, List AF: Targeting the multidrug resistance-1 transporter in AML: Molecular regulation and therapeutic strategies. *Blood* 104:1940-1951, 2004
43. Scholl C, Gilliland DG, Fröhling S: Deregulation of signaling pathways in acute myeloid leukemia. *Semin Oncol* 35:336-345, 2008
44. Mizutani K, Sugimoto K, Okuda T, et al: Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats. *Hypertens Res* 25:135-140, 2002
45. Ostergaard E: Disorders caused by deficiency of succinate-CoA ligase. *J Inher Metab Dis* 31:226-229, 2008
46. Greenlee MC, Sullivan SA, Bohlson SS: Detection and characterization of soluble CD93 released during inflammation. *Inflamm Res* 58:909-919, 2009
47. Gorczynski RM, Kai Y, Miyake K: MD1 expression regulates development of regulatory T cells. *J Immunol* 177:1078-1084, 2006
48. Wang C, Hayashi H, Harrison R, et al: Modulation of Mac-1 (CD11b/CD18)-mediated adhesion by the leukocyte-specific protein 1 is key to its role in neutrophil polarization and chemotaxis. *J Immunol* 169:415-423, 2002
49. Usdin TB, Modi W, Bonner TI: Assignment of the human PTH2 receptor gene (PTHR2) to chromosome 2q33 by fluorescence *in situ* hybridization. *Genomics* 37:140-141, 1996
50. Marcucci G, Mrózek K, Radmacher MD, et al: MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. *Best Pract Res Clin Haematol* 22:239-248, 2009
51. Bousquet M, Quelen C, Rosati R, et al: Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. *J Exp Med* 205:2499-2506, 2008
52. Takaya T, Ono K, Kawamura T, et al: MicroRNA-1 and microRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. *Circ J* 73:1492-1497, 2009
53. Bleeker FE, Lamba S, Leenstra S, et al: *IDH1* mutations at residue p.R132 (*IDH1*^{R132}) occur frequently in high-grade gliomas but not in other solid tumors. *Hum Mutat* 30:7-11, 2009
54. Schnittger S, Haferlach C, Ulke M, et al: *IDH1* mutations are detected in 9.3% of all AML and are strongly associated with intermediate risk karyotype and unfavourable prognosis: A study of 999 patients. *Blood* 114, 2009 (abstr LBA-3)
55. Baldus CD, Tanner SM, Ruppert AS, et al: *BAALC* expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study. *Blood* 102:1613-1618, 2003
56. Langer C, Radmacher MD, Ruppert AS, et al: High *BAALC* expression associates with other molecular prognostic markers, poor outcome and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. *Blood* 111:5371-5379, 2008
57. Marcucci G, Baldus CD, Ruppert AS, et al: Overexpression of the ETS-related gene, *ERG*, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. *J Clin Oncol* 23:9234-9242, 2005
58. Marcucci G, Maharry K, Whitman SP, et al: High expression levels of the ETS-related gene, *ERG*, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. *J Clin Oncol* 25:3337-3343, 2007
59. Heuser M, Beutel G, Krauter J, et al: High meningioma 1 (*MN1*) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. *Blood* 108:3898-3905, 2006
60. Langer C, Marcucci G, Holland KB, et al: Prognostic importance of *MN1* transcript levels, and biologic insights from *MN1*-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. *J Clin Oncol* 27:3198-3204, 2009
61. Metzeler KH, Dufour A, Benthaus T, et al: *ERG* expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of *ERG*, *MN1*, and *BAALC* transcript levels using oligonucleotide microarrays. *J Clin Oncol* 27:5031-5038, 2009
62. Thompson CB: Metabolic enzymes as oncogenes or tumor suppressors. *N Engl J Med* 360:813-815, 2009
63. Dang L, White DW, Gross S, et al: Cancer-associated *IDH1* mutations produce 2-hydroxyglutarate. *Nature* 462:739-744, 2009

